In Vitro Activity of a Novel Broad-Spectrum Antifungal, E1210, Tested against Aspergillus spp. Determined by CLSI and EUCAST Broth Microdilution Methods
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
E1210 is a first-in-class broad-spectrum antifungal that suppresses hyphal growth by inhibiting fungal glycophosphatidylinositol (GPI) biosynthesis. In the present study, we extend these findings by examining the activity of E1210 and comparator antifungal agents against Aspergillus spp. by using the methods of the Clinical and Laboratory Standards Institute (CLSI) and the European Committee for Antimicrobial Susceptibility Testing (EUCAST) to test wild-type (WT) as well as amphotericin B (AMB)-resistant (-R) and azole-R strains (as determined by CLSI methods). Seventy-eight clinical isolates of Aspergillus were tested including 20 isolates of Aspergillus flavus species complex (SC), 22 of A. fumigatus SC, 13 of A. niger SC, and 23 of A. terreus SC. The collection included 15 AMB-R (MIC, ≥2 μg/ml) isolates of A. terreus SC and 10 itraconazole-R (MIC, ≥4 μg/ml) isolates of A. fumigatus SC (7 isolates), A. niger SC (2 isolates), and A. terreus SC (1 isolate). Comparator antifungal agents included anidulafungin, caspofungin, amphotericin B, itraconazole, posaconzole, and voriconazole. Both CLSI and EUCAST methods were highly concordant for E1210 and all comparators. The essential agreement (EA; ±2 log 2 dilution steps) was 100% for all comparisons with the exception of posaconazole versus A. terreus SC (EA = 91.3%). The minimum effective concentration (MEC)/MIC 90 values (μg/ml) for E1210, anidulafungin, caspofungin, itraconazole, posaconazole, and voriconazole, respectively, were as follows for each species: for A. flavus SC, 0.03, ≤0.008, 0.12, 1, 1, and 1; for A. fumigatus SC, 0.06, 0.015, 0.12, >8, 1, and 4; for A. niger SC, 0.015, 0.03, 0.12, 4, 1, and 2; and for A. terreus SC, 0.06, 0.015, 0.12, 1, 0.5, and 1. E1210 was very active against AMB-R strains of A. terreus SC (MEC range, 0.015 to 0.06 μg/ml) and itraconazole-R strains of A. fumigatus SC (MEC range, 0.03 to 0.12 μg/ml), A. niger SC (MEC, 0.008 μg/ml), and A. terreus SC (MEC, 0.015 μg/ml). In conclusion, E1210 was a very potent and broad-spectrum antifungal agent regardless of in vitro method applied, with excellent activity against AMB-R and itraconazole-R strains of Aspergillus spp.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Aspergillosis: Spectrum of Disease, Diagnosis, and Treatment
Barnes, P. D., & Marr, K. A. (2006) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2006.06.001 · Cited by 205 · cited 1×
“The introduction of mold-active antifungal agents of the triazole (itraconazole, posaconazole, voriconazole) and echinocandin (anidulafungin, caspofungin, micafungin) classes has dramatically increased the options for prophylaxis and empirical or directed therapy for the prevention and treatment of invasive aspergillo…”
BackgroundIn Vitro Activity of E1210, a Novel Antifungal, against Clinically Important Yeasts and Molds
Miyazaki, M., Horii, T., Hata, K., Watanabe, N.-A., Nakamoto, K., Tanaka, K., Shirotori, S., Murai, N., Inoue, S., Matsukura, M., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00291-11 · Cited by 200
Cited by
Antifungal resistance: current trends and future strategies to combat
Wiederhold, N. (2017) · Infection and Drug Resistance · doi:10.2147/idr.s124918 · Cited by 468
The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin
Hoenigl, M., Sprute, R., Egger, M., Arastehfar, A., Cornely, O. A., Krause, R., Lass-Flörl, C., Prattes, J., Spec, A., Thompson, G. R., et al. (2021) · Drugs · doi:10.1007/s40265-021-01611-0 · Cited by 467
The Still Underestimated Problem of Fungal Diseases Worldwide
Almeida, F., Rodrigues, M. L., & Coelho, C. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.00214 · Cited by 445
The rapid emergence of antifungal-resistant human-pathogenic fungi
Lockhart, S. R., Chowdhary, A., & Gold, J. A. W. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00960-9 · Cited by 308
Shaw, K. J., & Ibrahim, A. S. (2020) · Journal of Fungi · doi:10.3390/jof6040239 · Cited by 229
“terreus and ITC-resistant Aspergillus [44].”
Metadata
- Authors
- Pfaller, M. A., Duncanson, F., Messer, S. A., Moet, G. J., Jones, R. N., & Castanheira, M.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2011-11
- Volume
- 55
- Issue
- 11
- Pages
- 5155-5158
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2110436000
- Cited by
- 74
- References
- 2
- FWCI
- 2.00
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: In Vitro Activity of a Novel Broad-Spectrum Antifungal, E1210, Tested against Aspergillus spp. Determined by CLSI and EUCAST Broth Microdilution Methods. https://app.cochat.ai/papers/10.1128/aac.00570-11
- The paper
- Pfaller, M. A., Duncanson, F., Messer, S. A., Moet, G. J., Jones, R. N., & Castanheira, M. (2011). In Vitro Activity of a Novel Broad-Spectrum Antifungal, E1210, Tested against Aspergillus spp. Determined by CLSI and EUCAST Broth Microdilution Methods. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00570-11
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.